To this end, the negative effects of TGR5 agonists on cholestasis, cholangiocyte proliferation, and hepatic cystogenesis decreases the enthusiasm of therapeutically targeting TGR5 to treat liver disease (Figure 3). Here, GPBAR1 is linked to liver disorder.